HCW BIOLOGICS INC (HCWB)
US40423R1059 - Common Stock
HCWB gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. Both the profitability and financial health of HCWB have multiple concerns. HCWB is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year HCWB has reported negative net income.
HCWB had a negative operating cash flow in the past year.
HCWB had negative earnings in each of the past 5 years.
In the past 5 years HCWB always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -143.05%, HCWB is not doing good in the industry: 84.31% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -143.05% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-47.84%
ROA(5y)-53.34%
ROE(3y)-83.53%
ROE(5y)-77.23%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
HCWB has a Gross Margin of 31.17%. This is in the better half of the industry: HCWB outperforms 75.94% of its industry peers.
HCWB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 31.17% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
HCWB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, HCWB has more shares outstanding
The debt/assets ratio for HCWB is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -9.74, we must say that HCWB is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -9.74, HCWB is doing worse than 74.51% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.74 |
ROIC/WACCN/A
WACC10.04%
2.3 Liquidity
A Current Ratio of 0.10 indicates that HCWB may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.10, HCWB is doing worse than 98.22% of the companies in the same industry.
HCWB has a Quick Ratio of 0.10. This is a bad value and indicates that HCWB is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of HCWB (0.10) is worse than 98.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.1 | ||
| Quick Ratio | 0.1 |
3. Growth
3.1 Past
HCWB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -66.67%.
Looking at the last year, HCWB shows a small growth in Revenue. The Revenue has grown by 2.96% in the last year.
Measured over the past years, HCWB shows a very negative growth in Revenue. The Revenue has been decreasing by -11.50% on average per year.
EPS 1Y (TTM)-66.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-236.66%
Revenue 1Y (TTM)2.96%
Revenue growth 3Y-11.5%
Revenue growth 5YN/A
Sales Q2Q%-0.51%
3.2 Future
HCWB is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.66% yearly.
Based on estimates for the next years, HCWB will show a very strong growth in Revenue. The Revenue will grow by 141.38% on average per year.
EPS Next Y16.94%
EPS Next 2Y9.48%
EPS Next 3Y2.66%
EPS Next 5YN/A
Revenue Next Year-42.44%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y141.38%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
HCWB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HCWB. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.48%
EPS Next 3Y2.66%
5. Dividend
5.1 Amount
No dividends for HCWB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
HCW BIOLOGICS INC
NASDAQ:HCWB (11/22/2024, 8:00:00 PM)
After market: 0.75 -0.02 (-2.6%)0.77
+0.06 (+8.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap29.12M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -143.05% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 31.17% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.15
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.1 | ||
| Quick Ratio | 0.1 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-66.67%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y16.94%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)2.96%
Revenue growth 3Y-11.5%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y